Summary
[IQVIA Oncology Dynamics (Mexico) is part of the IQVIA Global Oncology portfolio]
All regions of Mexico
This profile describes the Mexican dataset from the IQVIA Oncology Dynamics portfolio. The full portfolio is a global database comprising patient records spanning 20 countries:
- Australia
- Belgium
- Brazil
- Bulgaria
- China
- Czech Republic
- France
- Germany
- India
- Italy
- Japan
- Mexico
- Romania
- Saudi Arabia
- Slovakia
- South Korea
- Spain
- Turkey
- United Kingdom
- USA
IQVIA Oncology Dynamics (Mexico) part of the IQVIA Global Oncology portfolio, has complete patient oncology treatment information collected directly from physicians via a paper-based questionnaire. This profile describes the Mexican dataset from the IQVIA Oncology Dynamics portfolio. This database is not a statistical sample of the Mexican population; it is a descriptive cross-sectional database. There are a total of ~7,000 annual oncology drug-treated patients, and a total of ~35,000 patients to date.
The full IQVIA Global Oncology portfolio is a global database comprising patient records spanning 20 countries: Australia, Belgium, Brazil, Bulgaria, China, Czech Republic, France, Germany, India, Italy, Japan, Mexico, Romania, Saudi Arabia, Slovakia, South Korea, Spain, Turkey, United Kingdom, and USA.
IQVIA Oncology Dynamics (Mexico) part of the IQVIA Global Oncology portfolio, has complete patient oncology treatment information collected directly from physicians via a paper-based questionnaire. This profile describes the Mexican dataset from the IQVIA Oncology Dynamics portfolio. This database is not a statistical sample of the Mexican population; it is a descriptive cross-sectional database. There are a total of ~7,000 annual oncology drug-treated patients, and a total of ~35,000 patients to date.
The full IQVIA Global Oncology portfolio is a global database comprising patient records spanning 20 countries: Australia, Belgium, Brazil, Bulgaria, China, Czech Republic, France, Germany, India, Italy, Japan, Mexico, Romania, Saudi Arabia, Slovakia, South Korea, Spain, Turkey, United Kingdom, and USA.
IQVIA Oncology Dynamics (Mexico) part of the IQVIA Global Oncology portfolio, has complete patient oncology treatment information collected directly from physicians via a paper-based questionnaire. This profile describes the Mexican dataset from the IQVIA Oncology Dynamics portfolio. This database is not a statistical sample of the Mexican population; it is a descriptive cross-sectional database. There are a total of ~7,000 annual oncology drug-treated patients, and a total of ~35,000 patients to date.
(Approximately 35 days after the end of a quarter)
(Q1 2018 - Present)
The database consists of drug-treated patients with one of the following indications:
- ALL
- CML
- CLL
- NHL
- Breast
- NSCLC
- Prostate
- Colorectal
- Bladder
- Kidney
- Multiple Myeloma
- Pancreas
- Ovarian Melanoma
The database consists of drug-treated patients with one of the following indications:
- ALL
- CML
- CLL
- NHL
- Breast
- NSCLC
- Prostate
- Colorectal
- Bladder
- Kidney
- Multiple Myeloma
- Pancreas
- Ovarian Melanoma
The IQVIA Oncology Dynamics (Mexico) database is updated on a quarterly basis.
This profile was last updated for the B.R.I.D.G.E. TO DATA site on September 20, 2023.
Population Dynamics
There are a total of ~35,000 patients to date
There are a total of ~7,000 active oncology drug-treated patients.
[Not applicable, as this is a cross-sectional survey with natural fallout collection. More specifically, annual sample targets for the database are not collected by indication and instead there are selection criteria for physician case reports to remove any bias (i.e., natural fall out).
Physicians are required to report the first consecutive cases during the reporting period. There is a limit to the number of cases that any one physician can report, regardless of indication.]
The sample is not weighted in any way. It is meant to give a representative view of the treated prevalent cancer population.
(Not applicable, as data collection is still ongoing)
Demographic Data
(YOB is collected)
N/A
(Not applicable, as patients in the database are considered representative of the overall patient population)
N/A
(Not applicable, as patients in the database are considered representative of the overall patient population)
All areas of Mexico
(Year)
(Not applicable)
Information is collected on Risk Factors and Family History
Physician & Practioner Info
All physicians have a unique ID number; however, this information is not available in the database.
There are ~100 cancer-treating physicians
(Not applicable)
Diagnoses/Signs & Symptoms
Data collection covers all aspects of the patient’s chemotherapy treatment, from cancer diagnosis (including date of diagnosis and cancer type, respectable status, and disease progression), assignment therapy, date of therapy and details of the therapy administered, to full demographics that include stage of disease at diagnosis and at relapse. Regular reporting by a panel of physicians in France provides stability in the data.
Drug-treated patients are reported in the database:
1. Date of diagnosis and stage at diagnosis are captured. Therapy type at diagnosis is not necessarily captured unless the patient is newly diagnosed.
2. Patient's current treatment and one historic/previous treatment are captured. The dates of each reported therapy are also captured.
3. Full patient demographics are always captured.
(Only one Primary Cancer Diagnosis is listed)
Information is collected on family history and risk factors. However, no information is collected on height, weight, BMI, patient waist circumference, BP, or pulse rate.
The database consistes of drug-treated patients with one of the following indications:
- ALL
- CML
- CLL
- NHL
- Breast
- NSCLC
- Prostate
- Colorectal
- Bladder
- Kidney
- Multiple Myeloma
- Pancreas
- Ovarian Melanoma
Data are often collected on smoking status; however, there is no information regarding alcohol consumption.
Procedures
Information is available on:
- Regimen
- Route of admin
- Dose
- Quantity and frequency
- Current therapy
- Most recent previous line of therapy
- Current supportive therapy
- Maintenance therapy
- Therapy initiator
- Therapy context
Information is available on surgery, including stem cell transplant.
Information is available on:
- Biomarkers
- ECOG performance status
- Metastatic status
Additionally, data are captured on chromosomal abnormalities in CLL CML MM
Drug Information
Information is available on prescribed and administered drugs:
- Regimen
- Route of admin
- Dose
- Quantity and frequency
- Current therapy
- Most recent previous line of therapy
- Current supportive therapy
- Maintenance therapy
- Therapy initiator
- Therapy context
However, information on hospital drug treatment is limited.
Information is available on Regimen, and Route of administration.
Posology or daily dose information is available, but not strength
Information is available on Quantity and Frequency
However, this is limited by character length in data entry field.
NOTE: Some regimens have multiple drugs.
(Not applicable)
Generic and brand name (where applicable) is requested.
Information is available on adverse events/side effects
Biobanks
Genetic-PGx Data
Economic Data
(Not applicable)
(Not applicable)
(Not applicable)
Validation & Linkage
However, numerous quality checks are performed on the data collected to ensure accuracy
Linkage does exist
All Oncology Dynamics databases are linked; however, they are not linked to other IQVIA Health databases.
Administrative Information
Email: RWDassets@iqvia.com
Email: RWASMCTeam@iqvia.com
(IQVIA)
(Not applicable)
N/A
(Not applicable)
This is a subscription database available to the pharmaceutical industry. Interested clients should contact email RWDassets@iqvia.com for more information regarding access.
Please email database contact mentioned above regarding costs related to any project or direct query
Aggregated reports (excel, ppt, flatfiles, etc.)
Local BI software
(Not applicable; please contact IQVIA for information regarding publications)
Not applicable; please contact IQVIA for information regarding publications
Database Contact
Email: RWDassets@iqvia.com
Email: RWASMCTeam@iqvia.com
Literature References
Not applicable; please contact IQVIA for information regarding publications